Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Cilansetron Irritable Bowel Safety Trial Size Reflects FDA Concerns

Executive Summary

Solvay's proposed 1,000-patient pivotal safety trial for the irritable bowel syndrome drug cilansetron reflects FDA's concern about the size of the safety database for IBS therapies.

You may also be interested in...



Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”

Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy

Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”

Solvay plans to submit a "comprehensive appropriate use plan" for cilansetron in conjunction with its upcoming NDA filing for the irritable bowel syndrome therapy

Novartis Expects Zelnorm U.S. Approval Despite EU Filing Withdrawal

Novartis continues to expect U.S. approval of Zelnorm (tegaserod) despite problems with the marketing application for the irritable bowel syndrome therapy in Europe.

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel